Open Access Green as soon as Postprint is submitted to ZB.
		
    MicroRNA-182-5p and microRNA-205-5p as potential biomarkers for prognostic stratification of p16-positive oropharyngeal squamous cell carcinoma.
        
        Cancer Biomark. 33, 331-347 (2022)
    
    
    
	    BACKGROUND: MicroRNAs constitute promising biomarkers. OBJECTIVE: The aim was to investigate diagnostic and prognostic implications of miR-182-5p and miR-205-5p in p16-positive and p16-negative oropharyngeal squamous cell carcinomas (OPSCCs). METHODS: Expression of miR-182-5p, miR-205-5p were determined via quantitative real-time-PCR in fresh frozen tissues of 26 p16-positive, 19 p16-negative OPSCCs and 18 HPV-negative oropharyngeal controls. Associations between miRNA-expression, clinicopathological characteristics and prognosis were analyzed. RESULTS: Higher miR-182-5p expression was associated with significant inferior disease-specific survival for p16-positive OPSCCs (HR = 1.98E+09, 95% CI 0-Inf; P= 0.028) and a similar trend was observed for p16-negative OPSCCs (HR = 1.56E+09, 95% CI 0-Inf; P= 0.051). Higher miR-205-5p expression was associated with an inferior progression-free survival (HR = 4.62, 95% CI 0.98-21.83; P= 0.034) and local control rate (HR = 2.18E+09, 95% CI 0-Inf; P= 0.048) for p16-positive OPSCCs. CONCLUSIONS: Results indicate that miR-182-5p and miR-205-5p can further stratify patients with p16-positive OPSCC into prognostic groups.
	
	
      Impact Factor
		Scopus SNIP
		
		
		Altmetric
		
	    3.828
		0.750
		
		
		
	    Annotations
	    
		
		     
		    
		
	    
	
		
	
	    Special Publikation
	    
		
		     
		
	    
	
	
	
	    Hide on homepage
	    
		
		     
		
	    
	
	
        Publication type
        Article: Journal article
    
 
    
        Document type
        Scientific Article
    
 
     
    
    
        Keywords
        Oropharyngeal Squamous Cell Carcinomas ; Mir-182-5p ; Mir-205-5p ; Microrna ; P16
    
 
     
    
    
        Language
        english
    
 
    
        Publication Year
        2022
    
 
    
        Prepublished in Year
        2021
    
 
    
        HGF-reported in Year
        2021
    
 
    
    
        ISSN (print) / ISBN
        1574-0153
    
 
    
        e-ISSN
        1875-8592
    
 
    
     
     
	     
	 
	 
    
        Journal
        Cancer Biomarkers
    
 
	
    
        Quellenangaben
        
	    Volume: 33,  
	    Issue: 3,  
	    Pages: 331-347 
	    
	    
	
    
 
    
         
        
            Publisher
            IOS Press
        
 
         
	
         
         
         
         
         
	
         
         
         
    
         
         
         
         
         
         
         
    
        Reviewing status
        Peer reviewed
    
 
    
        Institute(s)
        Translational Metabolic Oncology  (IDC-TMO)
    
 
    
        POF-Topic(s)
        30203 - Molecular Targets and Therapies
    
 
    
        Research field(s)
        Radiation Sciences
    
 
    
        PSP Element(s)
        G-501000-001
    
 
     
     	
    
    
        WOS ID
        WOS:000782373500006
    
    
        Scopus ID
        85128493730
    
    
        PubMed ID
        34542062
    
    
        Erfassungsdatum
        2021-10-15